• Citer

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

par Girard, Nicolas;Ponce Aix, S;Cedres, S;Berghmans, Thierry ;Burgers, S;Toffart, Anne-Claire;Phalke, Swati Popat ;Janssens, A;Gervais, R;Hochstenbag, M;Cardoso da Silva, M.;Burger, I A;Prosch, Helmut;Stahel, R;Xenophontos, E;Pretzenbaher, Y;Neven, A;Peters, S.
Référence ESMO Open, 8, 3, page (101576)
Publication Publié, 2023-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Thymic malignancies are rare intrathoracic tumors, which may be aggressive and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic setting, with limited treatment options after the failure of first-line platinum-based chemotherapy. They are frequently associated with autoimmune disorders that also impact oncological management.